---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-007377"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:34:33.265380+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q1 cash $641.7M, rev $18.4M; FT596+R-CHOP IND, FT536 solid tumor on track

## Summary
- Q1 2022 revenue of $18.4M from Janssen/Ono collaborations; R&D expense $72.1M, G&A $20.7M.
- Cash, equivalents and investments $641.7M as of March 31, 2022.
- FT596+R-CHOP clinical protocol for first-line aggressive lymphoma to be submitted to FDA in 2Q22.
- FT536 CAR MICA/B NK cell product candidate on track for first patient treatment in 2Q22.
- Third IND candidate nominated under Janssen collaboration triggering preclinical milestone payment.

## SEC filing metadata
- accession: 0000950170-22-007377
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017022007377/0000950170-22-007377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017022007377/fate-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-007377
- JSON: https://secwatch.observer/filing/0000950170-22-007377.json
- Plain text: https://secwatch.observer/filing/0000950170-22-007377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.